COVID-19 Vaccine Antibody Response in a Single-Center Urban Hemodialysis Unit

Background: The longitudinal response to the COVID-19 vaccines among patients on hemodialysis with and without prior SARS-CoV-2 infection has not been well characterized. Methods: To guide vaccination strategies in patients on hemodialysis, it is critical to characterize the longevity and efficacy of the vaccine; therefore, we conducted a prospective single-center monthly antibody surveillance study between March 2021 and March 2022 to investigate the dynamic humoral response to a series of COVID-19 mRNA vaccines in patients on hemodialysis with and without prior SARS-CoV-2 infection. Monthly quantitative antibody testing was performed using the Beckman Coulter Access SARS-CoV-2 IgG Antibody Test & COPY;, which detects IgG antibodies targeting the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Results: This cohort of 30 participants (mean age: 61 & PLUSMN; 3 years) predominantly self-identified as African American (97%) and male (53%). Eight participants (27%) had recovered from COVID-19 (recovered) before the vaccine initiation. All participants received two vaccine doses, and 86.6% received a 6-month booster dose. Among patients naive to COVID-19, the antibody positivity rate (APR) was 55% post-first-dose, 91% post-second-dose, 50% pre-booster at 6 months, 100% post-booster, and 89% at 6 months post-booster. Recovered patients sustained a consistent 100% APR throughout the year. The naive patients demonstrated lower peak antibody levels post-second-dose than the recovered patients (17.9 & PLUSMN; 3.2 vs. 44.7 & PLUSMN; 5.6, p < 0.001). The peak antibody levels post-booster showed no significant difference between both groups (27.1 & PLUSMN; 3.9 vs. 37.9 & PLUSMN; 8.2, p = 0.20). Two naive patients contracted COVID-19 during the follow-up period. Conclusions: The patients naive to COVID-19 exhibited an attenuated and foreshortened antibody response following two doses of the mRNA vaccines compared with the recovered patients, who maintained 100% APR before the booster dose. The 6-month booster dose counteracted declining immunity and stimulated antibody responses in the naive patients, even in previously non-responsive patients. This observation implies that different booster vaccination strategies might be required for COVID-19-naive and -recovered patients. Post-vaccination antibody testing may serve as a valuable tool for guiding vaccination strategies.